Last reviewed · How we verify

IV Lidocaine

University of Washington · FDA-approved active Small molecule

IV lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

IV lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local anesthesia and infiltration anesthesia, Ventricular arrhythmias (acute management), Postoperative pain management.

At a glance

Generic nameIV Lidocaine
Also known aslidocaine infusion
SponsorUniversity of Washington
Drug classLocal anesthetic / Antiarrhythmic agent (Class IB)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia / Cardiology
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that works by inhibiting sodium influx through voltage-gated sodium channels, thereby stabilizing the neuronal membrane and raising the threshold for electrical excitability. This action prevents depolarization and propagation of action potentials in sensory and motor nerves. When administered intravenously, it also has systemic antiarrhythmic properties by suppressing ectopic cardiac activity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: